Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000232858 | SCV000288352 | benign | Neuroblastoma, susceptibility to, 3 | 2024-01-28 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001697260 | SCV000569805 | likely benign | not provided | 2023-05-16 | criteria provided, single submitter | clinical testing | See Variant Classification Assertion Criteria. |
Eurofins Ntd Llc |
RCV000484508 | SCV000859937 | benign | not specified | 2018-03-09 | criteria provided, single submitter | clinical testing | |
St. |
RCV000761110 | SCV000891025 | likely benign | Familial isolated pituitary adenoma | 2021-05-20 | criteria provided, single submitter | clinical testing | The ALK c.3837-9_3837-7dup splice region change has a maximum subpopulation frequency of 0.97% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/variant/2-29430144-G-GGGA?dataset=gnomad_r2_1). This population frequency exceeds the expected prevalence of a pathogenic variant causing ALK-related neuroblastic tumor susceptibility (BS1). In silico tools predict that this variant does not impact splicing (BP4). This variant been reported in >5 individuals without a personal or family history consistent with ALK-related neuroblastic tumor susceptibility (internal data). In summary, this variant meets criteria to be classified as likely benign based on the ACMG/AMP criteria: BS1, BP4. |
Sema4, |
RCV002257560 | SCV002528492 | benign | Hereditary cancer-predisposing syndrome | 2020-09-17 | criteria provided, single submitter | curation | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000484508 | SCV004038133 | benign | not specified | 2023-08-19 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV000484508 | SCV003839559 | likely benign | not specified | 2022-06-20 | no assertion criteria provided | clinical testing |